LLC Insight Holdings Group Reduces Stake in Hinge Health, Inc.

LLC Insight Holdings Group has reduced its holdings in Hinge Health, Inc. (NYSE:HNGE) by selling 65,581 shares on June 16, 2026. The transaction was not part of a prearranged trading plan.

Other Institutional Activity in Hinge Health

Several other institutional investors have also been active in Hinge Health. Insight Holdings Group, LLC, maintained its position with 9,375,164 shares valued at approximately $361.5 million. 11.2 Capital Management, LLC, held steady with 3,704,524 shares worth about $142.8 million. Deer Management Co. LLC added 2,633,707 shares, bringing its total to 2,633,707 shares valued at $101.6 million. Bit Capital GmbH reduced its holdings by 1,006,304 shares, now holding 2,309,797 shares valued at $89.1 million. RTW Investments, LP, significantly increased its position by 1,576,500 shares to a total of 1,930,000 shares, valued at $74.4 million.

Hinge Health, Inc. Stock Up 3.6%

Shares of NYSE:HNGE traded near $67.04. Hinge Health, Inc. has a market cap of approximately $5.19 billion, with a forward P/E ratio of 20.05 and a beta of 1.3. The stock's 52-week range is between $30.08 and $70.72. It has a 50-day moving average of $52.27 and a 200-day moving average of $47.78. The company's current ratio stands at 1.303, with a quick ratio of 1.039 and a debt-to-equity ratio of 2.237.

Recent Earnings

Hinge Health reported revenue of $646.3 million, with a revenue growth of 47.2%. However, the company is not yet profitable, showing a net margin of -78.95% and a return on equity of -136.00%. The next earnings report is scheduled for August 4, 2026.

Insider Buying and Selling at Hinge Health, Inc.

On June 16, 2026, LLC Insight Holdings Group sold 65,581 shares at an average price of $70.36. On the same day, Mecklenburg Gabriel M.I. executed transactions involving 50,000 shares, both buying and selling, with a planned sale at a price of $65.53 on June 5, 2026.

Analysts Set New Price Targets

On June 17, 2026, Baird maintained a hold rating with a $65.00 price target. On June 15, 2026, Raymond James and Canaccord Genuity both maintained buy ratings with targets of $80.00 and $76.00, respectively. Analysts generally maintain a buy consensus, with a mean target price of $79.73 based on 15 opinions.

About Hinge Health, Inc.

Hinge Health, Inc. is a healthcare company focused on using technology to improve musculoskeletal system care. The company offers a platform designed for acute injury, chronic pain, and post-surgical rehabilitation, using AI-powered motion tracking and proprietary wearable devices. Headquartered in San Francisco, California, and led by CEO Daniel A. Perez, Hinge Health serves primarily self-insured employers.

Bottom Line

LLC Insight Holdings Group's recent sale of Hinge Health shares is part of ongoing activity among institutional investors in the company. Hinge Health continues to be a point of interest due to its innovative approach in healthcare technology. Analysts remain optimistic, with a consensus buy rating, though investors should remember that insider transactions do not necessarily indicate future stock performance.